Tirzepatide
Also known as Mounjaro · Zepbound
A dual GLP-1 and GIP receptor agonist — the most effective FDA-approved weight-management peptide to date, the active ingredient in Mounjaro and Zepbound.
Definition
Tirzepatide is a 39-amino-acid peptide that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.
How Meto uses it.
Dispensed as compounded tirzepatide at 10 mg/mL in multi-dose vials. Titration protocol: from 2.5 mg weekly to a 7.5–15 mg target across 16–24 weeks. Administration: Weekly subcutaneous self-injection with insulin syringe, rotating injection sites. Common use case: Members whose response to semaglutide has plateaued.
Safety notes
- Contraindicated in personal or family history of medullary thyroid cancer or MEN 2
- Contraindicated in active pancreatitis
- Not for use in pregnancy (wash-out recommended ≥ 2 months before conception)
- Stop before elective anaesthesia per current GI-aspiration guidance
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
Why is tirzepatide more effective than semaglutide?
Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both GLP-1 and GIP. GIP adds its own effects on insulin sensitivity and fat metabolism that compound the GLP-1 signal.
Can I switch from semaglutide to tirzepatide?
Yes, and this is a common transition for members who have plateaued. The clinician maps your current semaglutide equivalent to a tirzepatide starting dose and re-titrates from there.
Is compounded tirzepatide safe?
When dispensed by a 503A pharmacy with batch-level third-party testing for identity, potency and contamination — yes. 'Research-chemical' tirzepatide sold without a prescription is a different category entirely and is not safe.
Read More
SemaglutideOzempic
A long-acting GLP-1 receptor agonist used for type-2 diabetes and chronic weight management — the active ingredient in Ozempic and Wegovy.
PeptideGLP-1 Receptor AgonistGLP-1 RA
A peptide drug class that mimics glucagon-like peptide-1 to slow gastric emptying, sharpen insulin response and quiet food-noise.
MechanismGIPGlucose-Dependent Insulinotropic Polypeptide
An incretin hormone released by gut K-cells after a meal — the second receptor targeted by tirzepatide, on top of GLP-1.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.